These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 3288807)

  • 1. Cytology, immunopathology and flow cytometry in the diagnosis of pleural and peritoneal effusions.
    Croonen AM; van der Valk P; Herman CJ; Lindeman J
    Lab Invest; 1988 Jun; 58(6):725-32. PubMed ID: 3288807
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Malignant mesothelioma: immunohistochemistry and DNA ploidy analysis as methods to differentiate mesothelioma from benign reactive mesothelial cell proliferation and adenocarcinoma in pleural and peritoneal effusions.
    Friedman MT; Gentile P; Tarectecan A; Fuchs A
    Arch Pathol Lab Med; 1996 Oct; 120(10):959-66. PubMed ID: 12046609
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunohistochemical differentiation of malignant mesothelioma, mesothelial hyperplasia and metastatic adenocarcinoma in serous effusions, utilizing staining for carcinoembryonic antigen, keratin and vimentin.
    Duggan MA; Masters CB; Alexander F
    Acta Cytol; 1987; 31(6):807-14. PubMed ID: 2447718
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Mesothelial cell. Cytology. Cytochemistry. Immunocytochemistry. Contribution of immunolabelling to the cytodiagnosis of serous effusions with cells of mesothelial aspect].
    Marsan C; Gaulier A; Sabatier P; Garcia R
    Arch Anat Cytol Pathol; 1993; 41(5-6):223-8. PubMed ID: 8135583
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunocytochemistry of malignant mesothelioma: OV632 as a marker of malignant mesothelioma.
    Delahaye M; Hoogsteden HC; Van der Kwast TH
    J Pathol; 1991 Oct; 165(2):137-43. PubMed ID: 1744800
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multiparameter flow cytometric DNA analysis of effusions: a prospective study of 36 cases compared with routine cytology and immunohistochemistry.
    Joseph MG; Banerjee D; Harris P; Gibson S; McFadden RG
    Mod Pathol; 1995 Aug; 8(6):686-93. PubMed ID: 8532707
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Significance of combining detection of E-cadherin, carcinoembryonic antigen, and calretinin in cytological differential diagnosis of serous effusion].
    Su XY; Li GD; Liu HB; Jiang LL
    Ai Zheng; 2004 Oct; 23(10):1185-9. PubMed ID: 15473932
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Use of immunohistochemistry in clinical cytology].
    Weintraub D; Weintraub J; Vassilakos P
    Ann Pathol; 1987; 7(1):25-30. PubMed ID: 3304314
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The immunohistochemical diagnosis of mesothelioma. Differentiation of mesothelioma and lung adenocarcinoma.
    Ordóñez NG
    Am J Surg Pathol; 1989 Apr; 13(4):276-91. PubMed ID: 2648877
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The value of calretinin and cytokeratin 5/6 as markers for mesothelioma in cell block preparations of serous effusions.
    Shield PW; Koivurinne K
    Cytopathology; 2008 Aug; 19(4):218-23. PubMed ID: 17916095
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The distinction of mesothelioma from adenocarcinoma in malignant effusions by electron microscopy.
    Kobzik L; Antman KH; Warhol MJ
    Acta Cytol; 1985; 29(3):219-25. PubMed ID: 3859121
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic significance of carcinoembryonic antigen in the differential diagnosis of malignant mesothelioma.
    Mezger J; Lamerz R; Permanetter W
    J Thorac Cardiovasc Surg; 1990 Dec; 100(6):860-6. PubMed ID: 2147220
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunocytochemical panel for distinguishing between carcinoma and reactive mesothelial cells in body cavity fluids.
    Politi E; Kandaraki C; Apostolopoulou C; Kyritsi T; Koutselini H
    Diagn Cytopathol; 2005 Mar; 32(3):151-5. PubMed ID: 15690338
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Scoring system for differential diagnosis of malignant mesothelioma and reactive mesothelial cells on cytology specimens.
    Kimura N; Dota K; Araya Y; Ishidate T; Ishizaka M
    Diagn Cytopathol; 2009 Dec; 37(12):885-90. PubMed ID: 19572412
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 9p21 Deletion in the diagnosis of malignant mesothelioma in serous effusions additional to immunocytochemistry, DNA-ICM, and AgNOR analysis.
    Onofre FB; Onofre AS; Pomjanski N; Buckstegge B; Grote HJ; Böcking A
    Cancer; 2008 Jun; 114(3):204-15. PubMed ID: 18306350
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Image cytometry: an aid for cytological diagnosis of pleural effusions.
    Osterheld MC; Liette C; Anca M
    Diagn Cytopathol; 2005 Mar; 32(3):173-6. PubMed ID: 15690335
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytogenetic analysis of effusions from malignant mesothelioma. A diagnostic adjunct to cytology.
    Granados R; Cibas ES; Fletcher JA
    Acta Cytol; 1994; 38(5):711-7. PubMed ID: 8091903
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunocytochemistry in the differential diagnosis of effusions: use of logistic regression to select a panel of antibodies to distinguish adenocarcinomas from mesothelial proliferations.
    Frisman DM; McCarthy WF; Schleiff P; Buckner SB; Nocito JD; O'Leary TJ
    Mod Pathol; 1993 Mar; 6(2):179-84. PubMed ID: 8483888
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DNA flow cytometry of pleural effusions. Comparison with pathology for the diagnosis of malignancy.
    Evans DA; Thornthwaite JT; Ng AB; Sugarbaker EV
    Anal Quant Cytol; 1983 Mar; 5(1):19-27. PubMed ID: 6846965
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vimentin, carcinoembryonic antigen and keratin in the diagnosis of mesothelioma, adenocarcinoma and reactive pleural lesions.
    al-Saffar N; Hasleton PS
    Eur Respir J; 1990 Oct; 3(9):997-1001. PubMed ID: 1705232
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.